JP5296701B2 - 線維性疾患および線維増殖性疾患を処置および診断するための方法 - Google Patents

線維性疾患および線維増殖性疾患を処置および診断するための方法 Download PDF

Info

Publication number
JP5296701B2
JP5296701B2 JP2009539524A JP2009539524A JP5296701B2 JP 5296701 B2 JP5296701 B2 JP 5296701B2 JP 2009539524 A JP2009539524 A JP 2009539524A JP 2009539524 A JP2009539524 A JP 2009539524A JP 5296701 B2 JP5296701 B2 JP 5296701B2
Authority
JP
Japan
Prior art keywords
subject
circulating
disease
fibroblasts
fibrotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009539524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511389A (ja
JP2010511389A5 (enExample
Inventor
ボーナ・メーラッド
マリー・ディ・バーディック
デイビッド・エイ・ジスマン
マイケル・ピー・キーン
ジョン・エイ・ベルペリオ
ロバート・エム・ストリーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2010511389A publication Critical patent/JP2010511389A/ja
Publication of JP2010511389A5 publication Critical patent/JP2010511389A5/ja
Application granted granted Critical
Publication of JP5296701B2 publication Critical patent/JP5296701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009539524A 2006-11-30 2007-11-30 線維性疾患および線維増殖性疾患を処置および診断するための方法 Active JP5296701B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87201906P 2006-11-30 2006-11-30
US60/872,019 2006-11-30
PCT/US2007/086167 WO2008067559A2 (en) 2006-11-30 2007-11-30 Methods for treating and diagnosing fibrotic and fibroproliferative diseases

Publications (3)

Publication Number Publication Date
JP2010511389A JP2010511389A (ja) 2010-04-15
JP2010511389A5 JP2010511389A5 (enExample) 2011-01-20
JP5296701B2 true JP5296701B2 (ja) 2013-09-25

Family

ID=39468768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539524A Active JP5296701B2 (ja) 2006-11-30 2007-11-30 線維性疾患および線維増殖性疾患を処置および診断するための方法

Country Status (5)

Country Link
US (2) US8114608B2 (enExample)
EP (1) EP2100140B1 (enExample)
JP (1) JP5296701B2 (enExample)
AU (1) AU2007325029B2 (enExample)
WO (1) WO2008067559A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009437A2 (en) 2006-07-18 2008-01-24 Noxxon Pharma Ag Sdf-i binding nucleic acids
KR101589442B1 (ko) * 2007-08-06 2016-02-01 녹손 파르마 아게 에스디에프-1 결합형 핵산 및 이의 용도
CA2745027A1 (en) * 2008-10-22 2010-04-29 Allocure, Inc. Methods of using sdf-1 (cxcl12) as a diagnostic and mesenchymal stem cell (multipotent stromal cell)-specific therapeutic biomarker for the treatment of kidney injury and other major organs
JP2012127879A (ja) * 2010-12-16 2012-07-05 Kanazawa Univ 腎症の進行度の判定方法並びに線維化抑制剤。
CN103376228B (zh) * 2012-04-27 2016-02-17 中国人民解放军军事医学科学院放射与辐射医学研究所 一种检测或辅助检测放射性肺纤维化的试剂盒
EP2972380A2 (en) * 2013-03-14 2016-01-20 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
JP6601707B2 (ja) * 2015-02-15 2019-11-06 国立大学法人金沢大学 線維化判定方法
JP7126668B2 (ja) * 2017-08-09 2022-08-29 国立大学法人金沢大学 膠原病判定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759036B1 (en) 1997-03-28 2004-07-06 The Picower Institute For Medical Research Fibrocyte-base vaccine formulations
US8293479B2 (en) 2002-05-02 2012-10-23 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies
JP4922560B2 (ja) * 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法

Also Published As

Publication number Publication date
AU2007325029A1 (en) 2008-06-05
JP2010511389A (ja) 2010-04-15
WO2008067559A3 (en) 2008-07-17
US8216796B2 (en) 2012-07-10
WO2008067559A2 (en) 2008-06-05
EP2100140B1 (en) 2015-05-06
AU2007325029B2 (en) 2013-09-12
US8114608B2 (en) 2012-02-14
US20100074887A1 (en) 2010-03-25
US20120094305A1 (en) 2012-04-19
EP2100140A4 (en) 2010-07-21
EP2100140A2 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
JP5296701B2 (ja) 線維性疾患および線維増殖性疾患を処置および診断するための方法
US9359402B2 (en) EphA2 T-cell epitope agonists and uses therefore
Chen et al. Leukocyte cell‐derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment
US9399675B2 (en) Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
EP2238241A2 (en) Selective differentiation, identification, and modulation of human th17 cells
Chen et al. The significance of titin antibodies in myasthenia gravis: correlation with thymoma and severity of myasthenia gravis
WO2011157905A1 (en) Polyclonal antibody binding to acetylated hmgb1
EP3010541B1 (en) A method of diagnosing a scoliotic subject
US20180280503A1 (en) Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
WO2011150509A2 (en) Methods of diagnosing asthma
Bruneau et al. Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation
US20100297147A1 (en) Compositions and methods for modulating tlr14 activity
US9945843B2 (en) Methods for identifying compounds that inhibit G protein-coupled receptor (GPR84) agonist-stimulated chemotaxis
Bonner et al. Expression of functional receptor activity modifying protein 1 by airway epithelial cells with dysregulation in asthma
US20200132673A1 (en) Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
US7838490B2 (en) Methods and compositions for inhibition of vascular permeability
Hermann et al. Lipocalin-2 levels in acute and chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation
US20130065825A1 (en) Compositions and Methods for Delaying Senescence or Cell Death in Neurons
KR20140109956A (ko) 테나신-c 및 류마티스 관절염에서의 이의 용도
Dong Investigation of TSG-6 as a Potential Biomarker and Therapeutic Target in Osteoarthritis
KR20080085923A (ko) 백혈구 기능 저해를 위한 조성물 및 방법
Ashley Fibrocytes, y-Herpesvirus and Periostin Augment Bleomycin-induced Lung Fibrosis.
Østergaard et al. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987
HK40016117A (en) A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
WO2007042778A2 (en) Monitoring cardiovascular disease by determining the expression of kir2ds2 and/or dap12

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130613

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5296701

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250